ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GSK vs REGN // PIOTROSKI F-SCORE QUALITY

GSK plc American (NYSE) VS. Regeneron Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: GSK 3 — REGN 9
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GSK VS. REGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GSK REGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% 9.40% +0.50 GSK /roic <GO>
EV/EBITDA & P/E Valuation 21.0x 20.2x +0.80 REGN /valuation <GO>
Free Cash Flow Yield 2.21% 5.14% -2.93 REGN /fcf-yield <GO>
Operating Margin 13.90% 24.90% -11.00 REGN /operating-margins <GO>
Net Profit Margin 10.90% 31.40% -20.50 REGN /net-margins <GO>
Revenue Growth (YoY) 8.80% 1.00% +7.80 GSK /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.44% -0.44 REGN /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 7.72 -3.98 REGN /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 8/9 8/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.8 53.0 -6.20 REGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.95 1.16 -0.21 REGN /macro-sensitivity <GO>
Forward P/E Multiple 30.5x 17.4x +13.10 REGN /forward-pe <GO>
Enterprise Scale & Market Cap $98.47B $84.30B $14.17B GSK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GSK REV REGN REV GSK GROSS % REGN GROSS % GSK FCF REGN FCF
FY 2025 — $14.34B — — — $4.33B
FY 2024 — $14.20B — — — $3.78B
FY 2023 — $13.12B — — — $4.00B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GSK // BETA 0.95
REGN // BETA 1.16